Simpson Thacher & Bartlett and Anderson Mori & Tomotsune have represented Blackstone in its 242 billion yen ($2.3 billion) acquisition of Takeda Consumer Healthcare, which turned to Nishimura & Asahi for advice. The deal is expected to close in March 2021.

Takeda Consumer Healthcare is a subsidiary of Takeda Pharmaceutical and a leading provider of over the counter (OTC) medicines in Japan.

According to Reuters, Takeda Pharmaceutical has been selling its OTC assets worldwide as it seeks to refocus its business and reduce debt from last year’s $59 billion acquisition of Shire.

The deal marks Blackstone’s second private equity transaction in Japan’s healthcare sector, following the acquisition of AYUMI Pharmaceutical in 2019.

Simpson Thacher partners Tony King, Shahpur Kabraji and Jonathan Goldstein led on the transaction. Meanwhile, the Nishimura team was led by partners Yo Ota, Hiroko Shibata and Taeko Morita.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

AZB, STB act on OYO’s $525 mln U.S. bet

by Nimitt Dixit |

AZB & Partners has acted for Oravel Stays, the parent of e-hotelier OYO, on its proposed $525 million acquisition of U.S. motel operator G6 Hospitality from PE fund Blackstone. Simpson Thacher & Bartlett acted for Blackstone on the deal.

Deals

STB, Nishimura, MHM act on $4 bln take-private offer for Japan’s Fuji Soft

by Asian Legal Business《亚洲法律杂志》 |

Nishimura & Asahi and Simpson Thacher & Bartlett are advising U.S. private equity firm KKR & Co on its plan to take Japanese system developer Fuji Soft under a management buyout worth about 600 billion yen ($4.09 billion).

Deals

Skadden, STB advise on Timee’s $435mln Japan IPO

by Nimitt Dixit |

U.S. law firm Skadden, Arps, Slate, Meagher & Flom has guided Timee, Inc, a Japanese on-demand job platform, on its $435 million initial public offering and listing on the Tokyo Stock Exchange. Simpson Thacher & Bartlett advised the international managers on the deal.